Pharmacology of purine nucleoside analogues.
Three new purine nucleoside analogues, pentostatin, cladribine and fludarabine, have demonstrated remarkable clinical activity in a variety of hematologic malignancies. Although they share structural similarities, their plasma pharmacology, metabolism, and mechanisms of action differ qualitatively and quantitatively. The plasma pharmacokinetics and the cellular pharmacodynamics are reviewed to provide a basis for dose schedules and rationales for combinations with other anticancer drugs.
Plunkett
W
W
Department of Clinical Investigation, University of Texas, M.D. Anderson Cancer Center, Houston, USA.
Gandhi
V
V
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D017338:Cladribine / Q000493:pharmacokinetics / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D015649:Pentostatin / Q000493:pharmacokinetics / Q000627:therapeutic use; D011684:Purine Nucleosides; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011684:Purine Nucleosides; D015649:Pentostatin; D017338:Cladribine; D014740:Vidarabine; C024352:fludarabine